drugset / Trial / NCT05851157

A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548

NCT05851157

Phase 1 Completed 73 enrolled Vertex Pharmaceuticals Incorporated
NaCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of VX-548 in healthy participants.

Timeline

Start
2023-05-03
Primary completion
2023-10-30
Completion
2023-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Suzetrigine Small molecule Oral

Indications

No indication recorded.